Increased expression of Excision repair cross-complementation group 1 (ERCC1) correlated with a better prognosis of cervical cancer and ERCC1 expression was a useful predictive marker of locally advanced squamous cell carcinoma of the head and neck in patients treated with cisplatin [19, 20]. This evidence concerns the gene ERCC1 and cervical carcinoma.